Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Immunoglobulin Light-chain Amyloidosis 3Amyloidosis 3

Interventions

Dexamethasone 7Calcium Dobesilate 5Filgrastim 4Cyclophosphamide 4miridesap 3ixazomib 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Peripheral Blood Stem Cell Transplantation 3Bortezomib 3venetoclax 2Tacrolimus 2Methylprednisolone 2Amifostine 2sargramostim 1pyroxamide 1pomalidomide 1nelarabine 1melflufen 1isatuximab 1fludarabine phosphate 1daratumumab 1X-Rays 1Topotecan 1Tetradecanoylphorbol Acetate 1Technetium Tc 99m Pyrophosphate 1Technetium 1Sunitinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Immunoglobulin Light-chain Amyloidosis × miridesap × Clear all
NCT01777243 2018-07-24

A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis

GlaxoSmithKline

Phase 1 Completed
25 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01406314 2017-06-09

SAP Depleter Dose Assessment Study in Patients

GlaxoSmithKline

Phase 1 Completed
17 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT02953808 2017-01-19

Phase 1 Study of GSK2315698 in Healthy Japanese Subjects

GlaxoSmithKline

Phase 1 Completed
18 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡